Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Transgene Reports Positive Data on its Tasly-Partnered HBV Therapy

publication date: Oct 23, 2017

Transgene reported its therapeutic hepatitis B vaccine was safe and promoted immunogenicity in a Phase I/Ib trial. A JV formed by France's Transgene and China's Tasly Pharma has filed for CFDA approval to begin clinical trials of TG1050 in China. With a single dose, TG1050 provoked a specific immune response in the first cohort of patients treated. The TG1050 immunotherapy was administered as an addition to a standard antiviral regimen, which can take as long as 15 years to cure hepatitis B. More details....

Stock Symbols: (Euronext: TNG) (SHA: 600535)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.